請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53618
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 于明暉(Ming-Whei Yu) | |
dc.contributor.author | Siao-Ning Huang | en |
dc.contributor.author | 黃筱寗 | zh_TW |
dc.date.accessioned | 2021-06-16T02:26:27Z | - |
dc.date.available | 2020-09-14 | |
dc.date.copyright | 2015-09-14 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-05 | |
dc.identifier.citation | 1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2095-128. 2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90. 3. World Health Organization. Fact sheet: hepatitis B. http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed May 30, 2015. 4. Chen CH, Yang PM, Huang GT, et al. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007;106(2):148-55. 5. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373(9663):582-92. 6. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009;49(5 Suppl):S45-55. 7. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45(4):529-38. 8. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142(6):1264-73 e1. 9. Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat 2009;16(7):453-63. 10. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365(12):1118-27. 11. Kew MC. Serum aminotransferase concentration as evidence of hepatocellular damage. The Lancet 2000;355(9204):591-2. 12. Kim WR, Flamm SL, Di Bisceglie AM, et al. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008;47(4):1363-70. 13. Lee PI, Chang MH, Lee CY, et al. Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children. Hepatology 1990;12(4 Pt 1):657-60. 14. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57(1):167-85. 15. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988;95(3):734-9. 16. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999;94(4):1018-22. 17. Nyblom H, Bjornsson E, Simren M, et al. The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int 2006;26(7):840-5. 18. Moussavian SN, Becker RC, Piepmeyer JL, et al. Serum gamma-glutamyl transpeptidase and chronic alcoholism. Influence of alcohol ingestion and liver disease. Dig Dis Sci 1985;30(3):211-4. 19. Cohen JA, Kaplan MM. The SGOT/SGPT ratio--an indicator of alcoholic liver disease. Dig Dis Sci 1979;24(11):835-8. 20. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11(2):97-107. 21. Su TH, Kao JH. Improving clinical outcomes of chronic hepatitis B virus infection. Expert Rev Gastroenterol Hepatol 2015;9(2):141-54. 22. Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006;11(6):669-79. 23. Zhuang H. [Updates of EASL clinical practice guidelines: management of chronic hepatitis B virus infection]. Zhonghua Gan Zang Bing Za Zhi 2012;20(6):427-9. 24. van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52(3):420-4. 25. Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32(4 Pt 1):828-34. 26. Wang CC, Tseng KC, Peng CY, et al. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir. J Gastroenterol Hepatol 2013;28(1):46-50. 27. Chen TH, Chen CJ, Yen MF, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 2002;98(2):257-61. 28. Witjes CD, Ijzermans JN, van der Eijk AA, et al. Quantitative HBV DNA and AST are strong predictors for survival after HCC detection in chronic HBV patients. The Netherlands journal of medicine 2011;69(11):508-13. 29. Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004;328(7446):983. 30. Tai DI, Lin SM, Sheen IS, et al. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009;49(6):1859-67. 31. Lin CL, Liao LY, Liu CJ, et al. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology 2007;45(5):1193-8. 32. Lai M, Hyatt BJ, Nasser I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007;47(6):760-7. 33. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45(2):507-39. 34. Wu CF, Yu MW, Lin CL, et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 2008;29(1):106-12. 35. Dong MH, Bettencourt R, Brenner DA, et al. Serum levels of alanine aminotransferase decrease with age in longitudinal analysis. Clin Gastroenterol Hepatol 2012;10(3):285-90 e1. 36. Siddiqui MS, Sterling RK, Luketic VA, et al. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology 2013;145(6):1271-9 e1-3. 37. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137(1):1-10. 38. Ruhl CE, Everhart JE. Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology 2012;55(2):447-54. 39. Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010;28(10):1660-5. 40. Yang H-I, Yuen M-F, Chan HL-Y, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. The Lancet Oncology 2011;12(6):568-74. 41. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011;53(3):1020-2. 42. Wan DW, Tzimas D, Smith JA, et al. Risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States. Am J Gastroenterol 2011;106(11):1994-2000. 43. Hung YC, Lin CL, Liu CJ, et al. Development of risk scoring system for stratifying population for hepatocellular carcinoma screening. Hepatology 2015;61(6):1934-44. 44. Sohn W, Jun DW, Kwak MJ, et al. Upper limit of normal serum alanine and aspartate aminotransferase levels in Korea. J Gastroenterol Hepatol 2013;28(3):522-9. 45. Lee DH, Ha MH, Christiani DC. Body weight, alcohol consumption and liver enzyme activity--a 4-year follow-up study. Int J Epidemiol 2001;30(4):766-70. 46. Papatheodoridis GV, Manolakopoulos S, Liaw YF, et al. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol 2012;57(1):196-202. 47. Papatheodoridis GV, Manesis EK, Manolakopoulos S, et al. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology 2008;48(5):1451-9. 48. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010;139(2):483-90. 49. Papatheodoridis GV, Chrysanthos N, Hadziyannis E, et al. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat 2008;15(6):434-41. 50. Singh S, Singh PP, Singh AG, et al. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013;108(6):881-91; quiz 892. 51. Tsan YT, Lee CH, Wang JD, et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012;30(6):623-30. 52. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics 2004;19(5):537-44. 53. Russo MW, Jacobson IM. How to use statins in patients with chronic liver disease. Cleve Clin J Med 2004;71(1):58-62. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53618 | - |
dc.description.abstract | 背景:肝臟酵素aspartate aminotransferase (AST)及alanine aminotransferase (ALT)是臨床上廣為用於定期追蹤的肝炎標記。研究已指出AST或ALT異常和末期肝病有關,肝細胞癌也包括在其中。然而目前對於AST或ALT異常定義之理想切點值仍有質疑。本研究針對慢性B型肝炎感染者,利用縱式分析評估不同切點定義之肝臟酵素異常值對於未來長期持續異常和肝細胞癌罹病風險的預測能力。 材料與方法:本研究使用縱式世代研究資料,族群來自1989-1992年間在台灣公保健診中心定期接受健康檢查的2,665名HBsAg陽性男性個案,並且持續從1994年追蹤到2014年。總計有12,754時點的AST測量值及14,550時點的ALT測量值資料。定義切點25及40 U/L作為肝臟酵素異常值,以logistic regression model計算相對危險性(odds ratio; OR)以及95%信賴區間,並且使用ROC (receiver operating characteristic)曲線下之面積(AUC)評估模式的預測能力。 結果:以切點為25 U/L,在追蹤19年期間,AST異常盛行率介於37.8%-57.3%,而相對應ALT異常盛行率介於48.3%-59.7%;以切點為40 U/L,AST異常盛行率介於8.4%-13.7%,而其相對應在追蹤22年期間的ALT異常盛行率介於15.3%-23.8%。基線肝臟酵素異常者在其追蹤十年期間,肝臟酵素會持續異常的相對危險性為2-4倍,且OR值會隨著追蹤期間的增加而下降,AST由4.52至2.55,而ALT由3.65至2.53。不論切點,多時點對於持續肝臟酵素活性異常的能力都要比單時點來的佳(單時點預測能力:對於AST,AUC=0.52-0.72,對於ALT,AUC=0.53-0.78;多時點預測能力:對於AST,AUC=0.72-0.84,對於ALT,AUC=0.72-0.84)。而在肝細胞癌的風險預測也有相同發現,使用基線ALT測量值,其AUC為0.74,當加入5年多時點ALT測量值時AUC為0.78,其顯著增加預測的辨別力(p=0.0105)。 結論:五年期間的多時點資料,提升對於長期肝臟酵素持續異常和肝細胞癌之罹病風險的預測能力。未來有必要利用多時點資料建立罹病風險預測模式。 | zh_TW |
dc.description.abstract | Background: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are widely adopted as clinical indicators of hepatitis during routine checkups. Elevated AST or ALT is associated with advanced liver diseases including hepatocellular carcinoma (HCC). However, there is still uncertainty in the optimal definition of cut-off values for elevated liver enzymes. This study aimed to evaluate the impact of different cut-off values of liver enzymes on subsequent long-term measurements of liver enzymes, and their predictive abilities for the risk of HCC during chronic hepatitis B virus (HBV) infection. Methods: We used a longitudinal cohort study database, which includes a total of 2,665 hepatitis B surface antigen (HBsAg)-positive male who were recruited during routine physical examination from government employee central clinics between 1989 and 1992, and followed from 1994 to 2014. There are 12,754 time-points measurements for AST and 14,550 time-points measurements for ALT. Cut-off values of 25 and 40 U/L were used to define elevated liver enzymes. Logistic regression model was used to determined odds ratios (ORs) and 95% confidence intervals (CIs), and derive the area under the receiver operating characteristic curves (AUCs). Results: When using 25 U/L cutoff, the prevalence of elevated AST during 19 years of follow-up was 37.8%-57.3%, and the corresponding prevalence for elevated ALT was 48.3%-59.7%. For 40 U/L as cutoff, the prevalence of elevated AST was 8.4%-13.7%, and the corresponding prevalence for elevated ALT was 15.3%-23.8% during 22 years of follow-up. Elevated liver enzyme at baseline was associated with 2- to 4-fold increase in risk for subsequent elevation of liver enzyme during following 10 years, with the ORs declining over time from 4.52 to 2.55 for AST; and 3.65 to 2.53 for AST. Regardless of cutoff values, incorporation of multiple time-points liver enzyme measurements into regression model significantly improved predictive abilities (for AST: AUC=0.52-0.72; for ALT: AUC=0.53-0.78) for liver enzyme abnormalities in subsequent years, as compared to single time-point measurement (for AST: AUC=0.72-0.84; for ALT: AUC=0.72-0.84). Similar associations were observed for predicting HCC. When using baseline ALT as measurement, the AUC was 0.74. While for measurements spanning over 5 years, the predictive power in terms of AUC was 0.78 that significantly improved discrimination performance (p=0.0105). Conclusion: Multiple time-points measurements of liver enzymes in 5 years increase long-term predictive abilities for persistent liver abnormalities and HCC. The multiple time-point data should be considered for constructing longitudinal predictive algorithm for population stratification for HCC risk. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T02:26:27Z (GMT). No. of bitstreams: 1 ntu-104-R02849021-1.pdf: 1600487 bytes, checksum: 4c3b48349752133875aeaa67f05f36a8 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 謝誌................................................. i 中文摘要............................................. ii 英文摘要............................................. iv 研究背景.............................................. 1 B型肝炎流行病學 ....................................... 1 肝臟酵素(AST、ALT)自然史與臨床應用 ..................... 1 肝臟酵素與抗病毒藥物 ................................... 2 肝臟酵素狀態與肝臟疾病之關聯 ............................ 3 長期肝臟酵素狀態與肝臟疾病之關聯 ........................ 4 肝臟酵素異常值之定義 ................................... 5 肝臟酵素運用於肝細胞癌罹病風險分數建構 ................... 5 研究理由 .............................................. 7 研究目的 .............................................. 7 材料與方法............................................. 8 研究設計 .............................................. 8 資料 ....................................................... 8 研究世代 ............................................... 8 藥物使用情形............................................ 9 主要變項肝臟酵素(AST、ALT)的測量與分組 ................... 9 統計分析 .............................................. 10 結果.................................................. 11 個案之基本特徵 ........................................ 11 肝臟酵素異常盛行率與基線肝臟酵素異常於不同追蹤年代之關聯性及預測能力 ................................................. 11 長期追蹤肝臟酵素持續異常及持續正常之盛行率 ................ 12 比較單時點與多時點對於不同追蹤年代肝臟酵素異常之預測能力 ... 12 2013至2014年間有回診之次族群其ALT異常與藥物使用情形之關係 ...................................................... 13 比較單時點與多時點ALT測量值對於肝細胞癌之預測能力 ......... 13 討論.................................................. 14 參考文獻............................................... 20 | |
dc.language.iso | zh-TW | |
dc.title | B型肝炎帶原者肝臟酵素異常之縱貫性分析 | zh_TW |
dc.title | Longitudinal Analysis on Episodes of Elevated Liver Enzymes in Hepatitis B | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 鄭尊仁(Tsun-Jen Cheng),陳保中(Pau-Chung Chen),何蘊芳(Yunn-Fang Ho),林志陵(Chih-Lin Lin) | |
dc.subject.keyword | aspartate aminotransferase (AST),alanine aminotransferase(ALT),B型肝炎帶原者, | zh_TW |
dc.subject.keyword | Aspartate aminotransferase (AST),alanine aminotransferase(ALT),hepatitis B carrier, | en |
dc.relation.page | 37 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-08-05 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 1.56 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。